Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Drug discovery and development

ViiV acquires Bristol-Myers Squibb’s HIV portfolio

Offices of ViiV Healthcare

Source: ViiV Healthcare

ViiV Healthcare has acquired Bristol-Myers Squibb’s HIV research and development assets

Specialist pharmaceutical company ViiV Healthcare has boosted its HIV portfolio following a multimillion dollar deal with Bristol-Myers Squibb.

The company, which has GlaxoSmithKline as a majority shareholder, has acquired Bristol-Myers Squibb’s HIV research and development assets and its preclinical and discovery stage research assets.

The deal, announced on 22 February 2016, means ViiV now has one of the most “robust HIV pipelines” in the industry, according to the company’s chief executive officer Dominique Limet.

Dominique Limet, chief executive officer of ViiV

Source: GSK

Dominique Limet, chief executive officer of ViiV, says the company now has one of the most “robust HIV pipelines” in the industry

“The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV,” he says.

Drugs in development, which now pass to ViiV, include phase lll fostemsavir, an attachment inhibitor for heavily treated patients that is expected to begin the US marketing approval process in 2018; preclinical and discovery phase products include a novel biologic with a triple mechanism of action.

ViiV Healthcare paid an initial US$317m upfront for the late stage HIV assets, with another US$518m for development and first commercial sale milestones as well as tiered royalties on sales.

Some US$33m was paid upfront for the preclinical and discovery stage assets and another US$587m to cover development and first commercial sales milestones.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200749

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Offices of ViiV Healthcare
  • Dominique Limet, chief executive officer of ViiV

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.